ERBB2 and neoplasm: Two additional multi-epitope vaccines based on optimized cryptic peptides have been recently patented: Vx-006, composed of three optimized cryptic peptides derived from three different TAA (MAGE, TERT, HER-2/neu), and Vbx-016 based on four optimized cryptic peptides derived from four tumor antigens (CEA, MAGE, TERT and HER-2/neu), but to date, no published results are available in the literature [82].